Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT01557959 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma of the Lung
Adenosquamous Cell Lung Cancer
Bronchoalveolar Cell Lung Cancer
Large Cell Lung Cancer
Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Squamous Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions

DRUG: cisplatin
BIOLOGICAL: pegfilgrastim
DRUG: erlotinib hydrochloride
OTHER: laboratory biomarker analysis
GENETIC: polymorphism analysis
OTHER: pharmacogenomic studies
GENETIC: genetic linkage analysis
DRUG: docetaxel

Sponsor

Wake Forest University Health Sciences

Collaborators

[object Object]
[object Object]